Cargando…

Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma

Peroxisome proliferator-activated receptor gamma (PPARG), a key transcription factor involved in lipid metabolism and glucose homeostasis, has been implicated in various types of cancer. However, its precise role in cancer remains unclear. In this study, we conducted a comprehensive pan-cancer analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ran, Yunsheng, Hu, Chujiao, Wan, Junzhao, Kang, Qian, Zhou, Ruixian, Liu, Ping, Ma, Dan, Wang, Jianta, Tang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690586/ https://www.ncbi.nlm.nih.gov/pubmed/38044948 http://dx.doi.org/10.3389/fphar.2023.1298341

Ejemplares similares

Large-Scale Transcriptome Analysis Identified a Novel Cancer Driver Genes Signature for Predicting the Prognostic of Patients With Hepatocellular Carcinoma
por: Li, Gao, et al.
Publicado: (2021)

The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications
por: Gold, Philip W.
Publicado: (2021)

The Genetics of PPARG and the Skeleton
por: Ackert-Bicknell, Cheryl, et al.
Publicado: (2006)

Relationship of PPARG overexpression with prognostic parameters in papillary thyroid carcinoma
por: Asya, Orhan, et al.
Publicado: (2022)

SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma
por: Jin, Xing, et al.
Publicado: (2021)

Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker
por: Xie, Pan, et al.
Publicado: (2022)

OSlihc: An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma
por: An, Yang, et al.
Publicado: (2020)

Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening
por: Hu, Chujiao, et al.
Publicado: (2022)

MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma
por: Gramantieri, Laura, et al.
Publicado: (2022)

PPARG as therapeutic target for antifibrotic therapy
por: Ghallab, Ahmed, et al.
Publicado: (2020)

An Integration of Network Pharmacology and Experimental Verification to Investigate the Mechanism of Guizhi to Treat Nephrotic Syndrome
por: He, Dan, et al.
Publicado: (2021)

Investigating the effect of Icaritin on hepatocellular carcinoma based on network pharmacology
por: Xue, Zhong, et al.
Publicado: (2023)

Integrated Analysis of the Expression Characteristics, Prognostic Value, and Immune Characteristics of PPARG in Breast Cancer
por: Wu, Jianbin, et al.
Publicado: (2021)

PPARG Binding Landscapes in Macrophages Suggest a Genome-Wide Contribution of PU.1 to Divergent PPARG Binding in Human and Mouse
por: Pott, Sebastian, et al.
Publicado: (2012)

Oncogenic drivers and mitochondrial dependency
por: Alvarez-Calderon, Francesca, et al.
Publicado: (2015)

MicroRNA-181a Functions as an Oncogene in Gastric Cancer by Targeting Caprin-1
por: Lu, Qiang, et al.
Publicado: (2019)

An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment
por: Du, Yingxi, et al.
Publicado: (2021)

The core role of macrophages in hepatocellular carcinoma: the definition of molecular subtypes and the prognostic risk system
por: Wang, Qiaona, et al.
Publicado: (2023)

Insight into Oncogenic Viral Pathways as Drivers of Viral Cancers: Implication for Effective Therapy
por: Elkhalifa, Ahmed M. E., et al.
Publicado: (2023)

Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C
por: Vollbracht, Claudia, et al.
Publicado: (2022)

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score
por: Li, Yongjiang, et al.
Publicado: (2022)

Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma
por: Zhou, Zheng, et al.
Publicado: (2022)

Efferocytosis signatures as prognostic markers for revealing immune landscape and predicting immunotherapy response in hepatocellular carcinoma
por: Xu, Ke, et al.
Publicado: (2023)

A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma
por: Li, Yaoting, et al.
Publicado: (2023)

Exploring the oncogenic roles of LINC00857 in pan-cancer
por: Ren, Xiaomin, et al.
Publicado: (2022)

Prognostic Implications of Pyroptosis-Related Gene Signatures in Lung Squamous Cell Carcinoma
por: Li, Tingting, et al.
Publicado: (2022)

Genetic Variability of RXRB, PPARA, and PPARG in Wegener's Granulomatosis
por: Wieczorek, Stefan, et al.
Publicado: (2009)

PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis
por: Sabatino, Lina, et al.
Publicado: (2012)

Association of FTO and PPARG polymorphisms with obesity in Portuguese women
por: Carlos, Fábio Ferreira, et al.
Publicado: (2013)

Associations between PPARG polymorphisms and the risk of essential hypertension
por: Cai, Gaojun, et al.
Publicado: (2017)

The Impact of PPARD and PPARG Polymorphisms on Glioma Risk and Prognosis
por: Ding, Xiaoying, et al.
Publicado: (2020)

ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis
por: To, Jeffrey C., et al.
Publicado: (2020)

Heterogeneity characterization of hepatocellular carcinoma based on the sensitivity to 5-fluorouracil and development of a prognostic regression model
por: Gu, Xinyu, et al.
Publicado: (2023)

Interpreting the Pharmacological Mechanisms of Huachansu Capsules on Hepatocellular Carcinoma Through Combining Network Pharmacology and Experimental Evaluation
por: Huang, Jihan, et al.
Publicado: (2020)

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth
por: Luraghi, Paolo, et al.
Publicado: (2012)

Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking
por: Khan, Shakeel Ahmad, et al.
Publicado: (2022)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

Investigating the cardioprotective effects of Fuzheng Yangxin recipe based on network pharmacology and experimental evaluation
por: Wang, Anzhu, et al.
Publicado: (2022)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma
por: Peng, Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_la36abj6d0563tvmskutvh9i68